Alps Advisors Inc. raised its stake in GALAPAGOS NV/S (NASDAQ:GLPG) by 23.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 90,848 shares of the biotechnology company’s stock after acquiring an additional 17,459 shares during the period. Alps Advisors Inc.’s holdings in GALAPAGOS NV/S were worth $10,214,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. AMP Capital Investors Ltd acquired a new position in GALAPAGOS NV/S in the 2nd quarter valued at $221,000. Provident Investment Management Inc. acquired a new position in shares of GALAPAGOS NV/S during the 2nd quarter worth $249,000. Stanley Laman Group Ltd. acquired a new position in shares of GALAPAGOS NV/S during the 2nd quarter worth $720,000. Bank of America Corp DE raised its holdings in shares of GALAPAGOS NV/S by 11.7% during the 2nd quarter. Bank of America Corp DE now owns 9,758 shares of the biotechnology company’s stock worth $899,000 after buying an additional 1,025 shares in the last quarter. Finally, Macquarie Group Ltd. raised its holdings in shares of GALAPAGOS NV/S by 13.5% during the 2nd quarter. Macquarie Group Ltd. now owns 9,865 shares of the biotechnology company’s stock worth $909,000 after buying an additional 1,170 shares in the last quarter. 14.58% of the stock is owned by hedge funds and other institutional investors.
A number of equities analysts have recently commented on the company. Credit Suisse Group set a $90.00 price target on GALAPAGOS NV/S and gave the stock a “hold” rating in a report on Friday. BidaskClub raised GALAPAGOS NV/S from a “sell” rating to a “hold” rating in a report on Friday, October 19th. Zacks Investment Research cut GALAPAGOS NV/S from a “buy” rating to a “hold” rating in a report on Friday, October 12th. JPMorgan Chase & Co. assumed coverage on GALAPAGOS NV/S in a report on Wednesday, September 12th. They set an “overweight” rating and a $140.00 price target for the company. Finally, Stifel Nicolaus boosted their price target on GALAPAGOS NV/S from $109.00 to $111.00 and gave the stock a “buy” rating in a report on Wednesday, September 12th. Five research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $114.29.
GALAPAGOS NV/S (NASDAQ:GLPG) last issued its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported ($0.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.41. The business had revenue of $59.27 million for the quarter, compared to analyst estimates of $50.58 million. GALAPAGOS NV/S had a negative return on equity of 13.26% and a negative net margin of 70.80%. Research analysts expect that GALAPAGOS NV/S will post -2.92 earnings per share for the current fiscal year.
GALAPAGOS NV/S Company Profile
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
Recommended Story: Average Daily Trade Volume – What You Need to Know
Want to see what other hedge funds are holding GLPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GALAPAGOS NV/S (NASDAQ:GLPG).
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.